The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Category Archives: Transhuman News
Whole-Genome Sequencing as an Alternative to Cytogenetics in AML, MDS – Oncology Learning Network
Posted: April 19, 2021 at 7:17 am
Whole-genomesequencing (WGS) could be an alternative to conventional cytogenetic analysis in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to a study published in the New England Journal of Medicine (N Engl J Med. 2021;384[10]:924-935).
Genomic analysis is essential for risk stratification in patients with AML or MDS, said Eric J. Duncavage, MD, Department of Pathology and Immunology, McDonnell Genome Institute, and the Divisions of Oncology and Biostatistics, Department of Medicine, Washington University School of Medicine, St. Louis, and colleagues.
DrDuncavage and colleaguesobtained the genomic profiles of 263 patients with myeloid cancers, including 235 patients who had undergone cytogenetic analysis. Using WGS, they detected all 40 recurrent translocations and 91 copy-number alterations that the cytogenetic analysis identified. In 40 patients (17%, n = 235), new clinically reportable genomic events were found.
Prospective sequencing was performed on samples taken from 117 consecutive patients over a median of 5 days and provided new genetic information in 29 patients (24.8%), which in turn, changed the risk category for 19 patients (16.2%).
The researchers concluded thatWGS provided rapid and accurate genomic profiling in patients with AML or MDS.Emily Bader
Follow this link:
Whole-Genome Sequencing as an Alternative to Cytogenetics in AML, MDS - Oncology Learning Network
Posted in Genome
Comments Off on Whole-Genome Sequencing as an Alternative to Cytogenetics in AML, MDS – Oncology Learning Network
Blood Clots, Birth Control, and the Johnson & Johnson Vaccine: What We Mean by Medical Risk – The New Republic
Posted: at 7:16 am
The greatest risk inequitably enforced in this country is the most essential: general well-being. It is allowable, under our present systems, for trans people, for women, for Black women in particular, for poor people, for fat people, for the mentally ill, for the chronically ill and disabled, all to have worse health outcomesthese things are accepted and narrated to us by powerful institutions as an unfortunate but inescapable fact of medicine. And in doing so, they reiterate that these people are of lesser value, and are in fact inconvenient. These people are a burden, and so they should be grateful for what they get.
There was a hope among some at the very early start of the pandemic that, as horrific as it was going to be, it might force people with privilege to see how inextricably all of our lives are intertwined, how the health of one person isnt just their health but yours, too. We had to learn to wear masks not to protect ourselves but to protect others. Those with money suffered inconvenience at the very least from the fact that the people who serve and enable their lifestyles had no access to health care, to childcare, to workplace protections, to a real, functioning social safety netto any of the things that would allow them to stay home when sick, instead of risking a widespread infection to pack boxes for Amazon.
It would be impossible, as well as wholly undesirable, to avoid risk entirely in medical enterprise. Medicine is science, and science is experimentation, and experimentation can only happen if we take risks. And theres just no such thing as a risk-free existence. Aversion to risk in some contexts contributed to the inequities were dealing with today: In the 1970s, the FDA decided women of childbearing age shouldnt participate in clinical trials, out of concern not for the participants themselves but for possible future fetuses. As a result, it became the norm for new medicine to be developed exclusively on men; eight of the 10 prescription drugs withdrawn from the market between 1997 and 2000 posed greater health risks for women than for men.
The problem arises when a constitutionally unequal system assumes that the calculus by which we accept risk is neutral, rather than critically analyzing not just how research and regulatory decisions are made but how services are both distributed and received. A medical establishment predicated on the acceptance of profit-driven health care will inevitably favor the wealthy and the powerful, at the expense of everyone else.
Posted in Immortality Medicine
Comments Off on Blood Clots, Birth Control, and the Johnson & Johnson Vaccine: What We Mean by Medical Risk – The New Republic
[Full text] Binding of the SARS-CoV-2 Spike Protein | HMER – Dove Medical Press
Posted: at 7:16 am
Introduction
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic and its damaging effects on both health and economics worldwide. Transmission and pathology of the virus appears to be mediated through the respiratory system via interaction of the viral spike protein with the ACE-2 receptor13 differentially presented on various cells within the respiratory system.4,5 Expression of ACE-2 has been reported on lung alveolar epithelial cells, enterocytes of the small intestine, circulatory endothelial cells, arterial smooth muscle cells,6 adipose tissue, bone marrow, duodenum, endometrium, heart, kidney, testis, and thyroid7 suggesting a potential direct effect of COVID-19 on those tissues. Additionally, infection with COVID-19 has been associated with significant liver injuries and altered liver function tests.8
Alterations in liver function have been attributed to secondary effects of cytokine cascade, hypoxia, underlying liver disease,911 or infection of ACE-2 positive cholangiocytes.12 There have also been reports of coronavirus particles in hepatocytes without a defined mechanism for infection.13
In a recent report studying the receptome of spike binding, ACE-2 was confirmed as the primary receptor for the spike protein via the binding domain (RBD) on the spike 1 portion of the molecule and the N-terminal-domain as the sites critical for virushost interaction.14 Additionally, the report described binding of the spike protein with ectopically expressed ASGR1 and KREMEN1 in transfected non-liver cells. The results strongly suggested the existence of additional entry points into cells for the SARS-CoV-2 virus via the spike protein. Differences in primary infection sites and clinical manifestations of SARS-CoV and SARS-CoV-2, both utilizing ACE-2 as the primary site of cellular infection, suggested that other cellular receptors may be involved in SARS-CoV-2 host interactions.14
E12 TERT-immortalized multi-lineage progenitor cells (MLPC) derived from human umbilical cord blood have been differentiated into immortalized AT2-like cells (AT2) (manuscript submitted) and fused directly with primary human hepatocytes to create immortalized hepatocyte-like cells (HLC).15 The resultant E12 AT2-like cells expressed the characteristics of small airway epithelial cells associated with alveolar type 2 cells and not alveolar type 1 cells. The E12/PHH fusion cells (HLC) expressed the characteristics of fully mature and highly differentiated hepatocytes.15
This report studied the interactions of the SARS-CoV-2 spike protein with potential receptors on human cord blood-derived MLPC differentiated AT2, HLC and primary human hepatocytes (PHH) by confocal analysis. The characteristics of spike protein binding were examined using biotinylated spike proteins and blockade of binding by un-labeled spike proteins, spike protein-directed neutralizing antibodies and an antibody directed against the hepatocyte surface membrane asialoglycoprotein receptor 1 (ASGr1). The results suggested that binding and inhibition analyses can be used to assess the potential mechanisms of viral host cell interactions with a myriad of different target cells in the body, but also to assess therapeutics designed to inhibit that binding.
Immortalized AT2 and HLC could provide accurate and reproducible tools to study the differential virushost interactions between these targets of COVID-19 infection and aid in the development of therapeutics designed to inhibit binding and infection by the SARS-CoV-2 virus. In addition, the potential binding of spike protein to the ASGr1 on hepatocytes suggested a mechanism of viral entry via the clathrin-coated pit receptor-mediated pathway and direct injury to the liver.16,17
MLPC are multi-potent non-hematopoietic stem cells isolated from human umbilical cord blood.15 Umbilical cord blood was collected as part of an FDA submission to market PrepaCyte-CB, a product to de-bulk cord blood for cryo-banking and transplantation. IRB approval of the studies was conducted by the University of Minnesota, the Saint Louis Cord Blood Bank and by Quorum Review Protocol #800, March 3, 2005. The cord blood samples were collected by the American Red Cross Cord Blood Program (Saint Paul, Minnesota) and Ridgeview Medical Center (Waconia, MN). Donations were collected with donor consent for research use only.
Briefly, isolated leukocytes were incubated overnight in MSCGM (PT-4105, Lonza, Walkerville, MD) after which non-adherent cells were removed. Cells were cultured in MSCGM until 8090% of cells had a fibroblastic morphology. These cells were transfected with the gene for TERT, as previously described15 and were cloned by limited dilution. The E12 clone was selected for both immortality and differentiating potential. The E12 MLPC, expanded and cryopreserved for over 14 years, were used as undifferentiated control cells and as the source of cells for the development of the AT2-like cells and the fusion partner in the development of MLPC/hepatocyte hybrid cells.15 For confocal analysis, E12 cells (106/mL in MSCGM, 200 L per well) were plated in non-coated 16 well chamber slides (Nalge, Nunc International, Rochester, NY) and allowed to attach overnight before use in the analysis.
AT2-like cells were developed from the differentiation of E12 MLPC. Briefly, E12 cells (3 x 105 cells/mL) in MSCGM were added to non-coated tissue culture vessels and allowed to attach overnight. Medium was then exchanged with SAGM (SAGM, Lonza, Walkerville, MD, cat # 3118) and allowed to culture for 814 days with 3 medium changes per week. Upon achieving 70% confluence, cells were harvested by treatment with Tryp-LE (12605028, Life Technologies, Grand Island, NY) allowed to dissociate from the culture vessel and used for confocal analysis, as a positive control for binding spike proteins and ACE-2 expression. Cells (106/mL in SAGM, 200 L per well) were plated in non-coated 16 well chamber slides and allowed to adhere overnight prior to confocal analysis.
Hepatocyte-like fusion cells were created by the fusion of E12 MLPC with primary human hepatocytes, as previously described.15 Equal numbers of E12 MLPC and primary hepatocytes were fused using 50% polyethylene glycol in RMPI + 0.01% EDTA. Resultant cells were plated into collagen-coated 75 cm2 tissue culture flasks and were cultured for 7 days in RPMI + 20% FBS. After 7 days, non-fused PHH were no longer viable and did not contribute to the HLC cell lines. HLC were examined for hepatocyte-specific markers including albumin and urea production. HLC were demonstrated to express markers and production consistent with fully mature and well-differentiated hepatocytes. HLC (106/mL in hepatocyte expansion medium, 200 L per well) were plated in collagen-coated 16 well chamber slides and were allowed to adhere overnight prior to confocal analysis. Hepatocyte expansion medium consisted of Williams Medium E supplemented with 2% fatty acid-free BSA (Sigma, A7030), 1% ITS solution (Lonza, 17838Z), 5mM hydrocortisone 21-hemisuccinate (Sigma, H2270) and glutamax (35050, Gibco) supplemented with FGF basic (20 ng/mL) (233-FB), FGF-4 (20 ng/mL) (7460-F4), HFG (40 ng/mL) (294-HG), SCF (40 ng/mL) (255-SC), Oncostatin M (20 ng/mL) (295-OM), BMP-4 (20 ng/mL) (314-BP), EGF (40 ng/mL) (236-EG) and IL-1 (20 ng/mL)(201-LB) all from R&D Systems (Minneapolis, MN).
Cryo-preserved primary human hepatocytes and media were obtained from Zenotech (Kansas City, KS). Cells were thawed with OptiThaw medium and enumerated with OptiCount medium in a standard hemacytometer. Hepatocytes were diluted to a final concentration of 106 cells/mL of OptiPlate medium and were plated in collagen-coated 16 well chamber slides at 200 L per well. After 4 hours of plating, the medium was changed to OptiCulture medium to allow overnight attachment and spread of cells prior to confocal analysis.
Cells were prepared for staining with antibodies and binding of spike proteins by fixing the cells in 1% formaldehyde for 1 hour. Cells were then washed x 2 with PermaCyte permeabilization medium (WBP-1000, CMDG, St. Paul, MN). All staining took place in the presence of PermaCyte. Cells were incubated with an unlabeled primary antibody (100 ng) for 30 minutes at room temperature. ACE-2 (labeled with alexa 594, FAB9332T), albumin (MAB1456) and asialoglycoprotein receptor 1 (MAB4394) antibodies were obtained from R&D Systems (Minneapolis, MN). Unbound antibody was removed by washing with PermaCyte and the cells were counterstained with a secondary antibody specific for mouse (A-11005) antibody labelled with Alexa 594 dye (Life Technologies, (Eugene, OR)). Marker expression was confirmed by positive staining when compared to cells stained with antibody isotype controls (QTC1000, CMDG, St. Paul, MN). The nuclei of the cells were visualized by staining with DAPI.
The binding of SARS-CoV-2 spike and spike 1 proteins was analyzed by confocal microscopy using biotinylated spike proteins. Cells were prepared as described above. Cells were labelled with 250 ng of either biotinylated spike (RBD) (SPD-C8E9, ACROBiosystems, Newark, DE) or biotinylated spike 1 protein (SIN-C82E8, ACROBiosystems) for 30 minutes. Unbound spike proteins were removed by washing cells twice with PermaCyte medium. Bound spike proteins were visualized by secondary staining with streptavidin-alexa 594 (S11227 Life Technologies). Cells were counterstained with DAPI to visualize the nuclei.
Specificity of biotinylated spike proteins binding to the cells was confirmed by blockade of binding by a 5 molar excess of unlabeled spike protein. Cells were prepared as per the confocal analysis of antibody binding. Cells were incubated with 1.25 g of unlabeled spike protein (ACROBiosystems, SPD-S52H6) or spike 1 protein (ACROBiosystems, S1N-C52H3) for 1 hour. Without washing the unbound unlabeled spike protein, biotinylated spike and spike 1 proteins were added to the cells and incubated for 30 minutes. Cells were washed twice with PermaCyte medium to remove any unbound proteins. Bound biotinylated spike proteins were observed by secondary labeling with streptavidin-alexa 594. Cells were counterstained with DAPI to visualize the nucleus.
The effects of antibodies on the binding of the spike proteins to the cells were examined using two commercially available neutralizing antibodies obtained from ACROBiosystems (SAD-S35) and Novatein Biosystems (PR-nCOV-mABS1, Boston, MA) and the ASGr1-specific antibody (R&D Systems). One g of either neutralizing antibody was preincubated with the spike protein for one hour prior to the addition of the mixture to the cells prepared as described for binding of the spike proteins. The ASGr1 antibody (300 ng) was preincubated with cells prior to the addition of the spike protein. Visualization of the binding of biotinylated spike protein was accomplished by secondary staining with streptavidin-alexa 594. The nuclei of the cells were visualized with DAPI.
Cells were analyzed on the Olympus Fluoview 1000 confocal microscope. The confocal images in Figures 14 are representative of at least 3 studies done on different days.
Figure 1 Biotinylated spike and spike 1 protein binding to E12 differentiated AT2-like cells and inhibition by unlabeled spike protein and neutralizing antibodies. Bound biotinylated spike proteins were visualized by sequential labeling with streptavidin-alexa 594. Cells positive for binding are shown by red fluorescence. Blue nuclei were visualized by counterstaining with DAPI. (A) Binding of biotinylated spike protein (containing RBD). (B) Inhibition of biotinylated spike protein binding by co-incubation with a 5 molar excess of unlabeled spike protein (RBD). (C) Binding of spike 1 protein. (D) Inhibition of biotinylated spike protein binding by preincubation with a neutralizing antibody from ACROBiosystems. (E) Lack of binding inhibition by neutralizing antibody from Novatein Bio. (F) Inhibition of biotinylated spike 1 binding by unlabeled spike (RBD) protein.
Abbreviation: RBD, receptor-binding domain.
Figure 2 Expression of ACE-2, ASGr1 and serum albumin. Undifferentiated E12 MLPC data are shown in (AD). E12 HLC fusion cell results are presented in (EH). Primary human hepatocytes (PHH) are shown in (IL). Cells were incubated with unlabeled primary antibody and sequentially stained with secondary antibody labeled with alexa-594. Positive binding is shown by red fluorescence. Blue nuclei were visualized by DAPI counterstaining. Figures (A, E and I) were stained with isotype control antibodies. Figures (B, F and J) were stained with antibody specific for ACE-2. Figures (C, G and K) were stained with antibody specific for the asialoglycoprotein receptor 1 (ASGr1). Figures (D, H and L) were stained with antibody specific for serum albumin.
Figure 3 Undifferentiated E12 MLPC confocal microscopy is shown in (AD). E12 HLC fusion cell data are presented in (E-H). Primary human hepatocytes (PHH) are shown in (IL). Positive binding is indicated by red fluorescence. Blue nuclei were visualized with DAPI counterstaining. Figures (A, E and I) were labeled with Sav-594. Figures (B, F and J) were labeled with biotinylated spike protein followed by sequential staining with streptavidin-alexa 594. Figures (C, G and K) were labeled with biotinylated spike 1 protein followed by sequential staining with streptavidin-alexa 594. Figures (D, H and L) biotinylated spike protein binding was blocked by a 5 molar excess of unlabeled spike protein (RBD) followed by sequential staining with streptavidin-alexa 594.
Figure 4 Inhibition of biotinylated spike binding by neutralizing antibodies to spike 1, spike and ASGr1. E12 HLC fusion cell data are shown in (AD). Primary human hepatocytes (PHH) are shown in (EH). Positive binding of biotinylated spike proteins is shown by red fluorescence. Blue nuclei are visualized by counterstaining with DAPI. Figures (A and E) confocals show the inability of a 5 molar excess of unlabeled spike 1 protein to block the binding of biotinylated spike protein. Figures (B and F) show inhibition of binding of biotinylated spike protein by neutralizing antibody from ACROBiosystems. Figures (C and G) show binding inhibition of biotinylated spike protein by neutralizing antibody from Novatein Bio. Figures (D and H) demonstrate inhibition of any detectable binding of biotinylated spike protein by antibody specific for the hepatocyte membrane ASGr1.
In a parallel study that surveyed the differentiation of E12 MLPC to AT2-like cells, it was demonstrated that AT2-like cells were positive for markers associated with AT2 cells (surfactant protein C, ACE2, TM4SF1, HT2-280), negative for markers associated with AT1 cells (AGER, caveolin 1 and aquaporin) and positive for markers not unique to AT2 cells but known to be expressed on AT2 cells (CK19, CD26 and EpCAM). These results were identical to primary small airway epithelial cells. Both cell types were also shown to bind spike and spike 1 proteins. Biotinylated spike proteins could be blocked by unlabeled spike protein (RBD). Pre-incubation with neutralizing antibodies prevented the binding of biotinylated spike protein by the ACROBiosystems neutralizing antibody, but not the Novatein antibody. Expressions of ACE-2, spike protein binding and inhibition were repeated for this study to confirm the involvement of the ACE-2 receptor (Figure 1).
The expressions of ACE-2, ASGr1 and albumin in control E12 MLPC, HLC and PHH were studied by antibody staining. E12 MLPC were shown to be negative for ACE-2, ASGr1 and albumin expression. In contrast, ASGr1 and albumin were shown to be strongly expressed by both HLC and PHH. ACE-2 was not detectible in either cell type (Figure 2).
The ability of E12 MLPC, HLC and PHH to bind spike and spike 1 proteins was studied using biotinylated spike proteins. E12 MLPC were unable to bind either spike or spike 1 proteins. HLC and PHH were able to bind spike protein but not spike 1 protein. The binding of biotinylated spike protein could be blocked by pre-incubation with unlabeled spike protein (Figure 3). The binding of biotinylated spike protein could not be blocked by spike 1, but could be blocked by ACROBiosystems and Novatein neutralizing antibodies and also an antibody directed against the ASGr1 (Figure 4).
It is critical to elucidate the mechanisms of virus/host interactions of the SARS-CoV-2 for the development of therapeutics designed to inhibit the binding and internalization of the virus to a myriad of cell types. The overarching strategy for the development of vaccines or therapeutics has involved the interaction between the S1 portion of the viral spike protein and the ACE-2 cellular receptor found in the respiratory tract and in various other tissues.47 Differences in transmission, pathology and organ involvement between SARS-CoV and SARS-CoV-2 (both dependent upon ACE-2 binding) suggested that additional receptors may contribute to the attachment and internalization of the SARS-CoV-2 virus14 in both the respiratory lungs and other organ systems.
The potential infection of tissues that are ACE-2 negative has spurred the search for additional receptor interactions of the spike protein. Some of these potential spike protein receptor targets include neuropilin-1,18 ASGR1 and KREMEN1.14 The observation of SARS-CoV-2 particles in hepatocytes8 and the robust expression of ASGr1 receptors and neuropilin-1 on hepatocytes suggested that altered liver function associated with COVID-19 infection may be directly caused by infection with the virus and mediated by binding to one or both receptors.
We investigated the potential virus: receptor interactions via the spike protein using fluorescent confocal microscopy and biotinylated spike (RBD) and spike 1 proteins. In a parallel study, E12 MLPC were differentiated to AT2-like cells (manuscript submitted). These cells expressed markers associated with AT2 cells (surfactant protein C, ACE2, TM4SF1, HT2-280), negative for markers associated with AT1 cells (AGER, caveolin 1 and aquaporin) and positive for markers not unique to AT2 cells but known to be expressed on AT2 cells (CK19, CD26 and EpCAM). These results were identical to primary small airway epithelial cells. The binding of biotinylated spike proteins and specific blocking by unlabeled protein and neutralizing antibodies confirmed that the primary interaction of spike protein with AT2-like cells and primary small airway epithelial cells was via the S1 portion of the protein with the ACE-2 receptor. We repeated those studies in support of our findings with the HLC and PHH. The differential inhibition of spike protein binding with two different antibodies suggested that viral neutralization could result from mechanisms other than direct inhibition of S1 (RBD) binding to ACE-2.
The characteristics of SARS-CoV-2 interactions with hepatocytes were studied by observing the binding of biotinylated spike (RBD) and spike 1 proteins to HLC and PHH using the undifferentiated E12 as a known negative control. It was observed that HLC and PHH were both negative for ACE-2, precluding that as a potential site of viral binding. This was confirmed by the inability of the cells to bind S1 protein. The binding of biotinylated spike protein and blockade by unlabeled spike protein on HLC and PHH suggested that the binding was specific, and via a mechanism distinct from ACE-2. The complete inhibition of spike binding by an antibody directed against the ASGr1 is strongly suggestive that ASGr1 is a binding site for the spike protein on hepatocytes. Interestingly, blockade of spike binding by both neutralizing antibodies on HLC and PHH was distinct from AT2 cells where inhibition occurred solely with the antibody that was directed against the RBD. This is suggestive of neutralizing activity that can occur outside the RBD.
Utilization of multiple cell types to study the interactions of spike protein binding will help identify additional receptor pathways for infection with COVID-19. They could also provide a powerful tool to aid in the development of therapeutics against multiple sites on the spike protein or receptors of the host cells. With the existent emergence of new variants and mutations of the SARS-CoV-2 exhibiting enhanced transmissibility, it is especially important to expand our repertoire of cellular models to investigate the effects of the mutations on the binding characteristics of the virus to host cells. The availability of immortalized cells with the stable characteristics of human alveolar type 2 cells and mature well-differentiated hepatocytes could provide an accurate and reproducible tool to effectively study the various virushost interactions via spike proteins by providing potential viral receptors that are segregated according to cell type. We believe that AT2 and HLC provide such a tool.
Dr Daniel P Collins reports personal fees from BioE, LLC, during the conduct of the study. In addition, Dr Daniel P Collins has a patent Composition for an in vitro culture medium to maintain and expand stem cell-derived hepatocyte-like cells pending, as well as,a patent Methods to develop immortalized hybrid hepatocyte-like cells, also pending. The authors report no other conflicts of interest in this work.
1. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA. 2020;117(21):1172711734. doi:10.1073/pnas.2003138117
2. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215220. doi:10.1038/s41586-020-2180-5
3. Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413
4. Hikmet F, Mar L, Edvinsson , et al. The protein expression profile of ACE2 in human tissues. Mol Sys Biol. 2020;16(7):e9610. doi:10.15252/msb.20209610
5. Sungnak W, Huang N, Bcavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681687. doi:10.1038/s41591-020-0868-6
6. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS corona virus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631637. doi:10.1002/path.1570
7. Wang D, Eraslan B, Weiland T, et al. A deep proteome and transcriptome abundance atlas of 29 healthy human tissues. Mol Syst Biol. 2019;15(2):e8503. doi:10.15252/msb.20188503
8. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73(4):807816. doi:10.1016/jhep.2020.05.002
9. Desai N, Neyaz A, Szabolcs A, et al. Temporal and spatial heterogeneity of host response to SARS-CoV pulmonary infection. Nat Comm. 2020;11(1):6319. doi:10.1038/s41467-020-20139-7
10. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):10331034. doi:10.1016/S0140-6736(20)30628-0
11. Chu H, Chan JF, Wang Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020;71(6):14001409. doi:10.1093/cid/ciaa410
12. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. doi:10.1107/2020.02.03.931/766
13. Lozano-Sepulveda SA, Galan-Huerta K, Martnez-Acua N, Arellanos-Soto D, Rivas-Estilla AM. SARS-CoV-2 another kind of liver aggressor, how does it do that? Ann Hepatol. 2020;19(6):592596. doi:10.1016/j.aohep.2020.08.062
14. Gu Y, Cao J, Zhang X, et al. Interaction network of SARS-CoV-2 with host receptome through spike protein. bioRxiv. 2020. doi:10.1101/2020.09.09.28/508
15. Collins DP, Hapke JH, Aravalli RN, Steer CJ. Development of immortalized human hepatocyte-like hybrid cells by fusion of multi-lineage progenitor cells with primary hepatocytes. PLoS One. 2020;15(6):e234002. doi:10.1371/journal.pone.0234002
16. DSouza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting strategies and applications. J Control Release. 2015;203:126139. doi:10.1016/j.jconrel.2015.02.022
17. Huang X, Leroux JC, Castagner B. Well-defined multivalent ligands for hepatocytes targeting via asialoglycoprotein receptor. Bioconjug Chem. 2017;28(2):283295. doi:10.1021/acs.bioconjchem.6b00651
18. Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370:861865. doi:10.1126/science.abd3072
Originally posted here:
[Full text] Binding of the SARS-CoV-2 Spike Protein | HMER - Dove Medical Press
Posted in Immortality Medicine
Comments Off on [Full text] Binding of the SARS-CoV-2 Spike Protein | HMER – Dove Medical Press
[Full text] DNA Methylation of Fluoxetine Response in Child and Adolescence: Preli | PGPM – Dove Medical Press
Posted: at 7:12 am
Introduction
Antidepressants are a first-line treatment for major depressive disorder (MDD) and are widely prescribed for other conditions, such as obsessive-compulsive disorder (OCD). However, between 40% and 50% of patients on antidepressants do not respond to treatment or relapse.1,2 This individual variability could be due to the complexity of antidepressant response that involves the interplay of both environmental and genetic factors.3 There are currently no specific sociodemographic or clinical markers to predict the response to antidepressants.4
Pharmacogenetic studies have shown that genetic variation influences antidepressant response, but have not fully explained individual variability.5 Recent reports have indicated that the estimates of heritability due to common genetic variants are lower than expected and that significant associations are poorly replicated.6,7 Thus, the search for biomarkers other than genetic factors that predict antidepressant response is gaining increasing attention,3 with epigenetic markers, especially DNA methylation, attracting a lot of interest.8
DNA methylation involves the addition of a methyl group at position 5 of the cytosine pyrimidine ring, a reaction catalyzed by members of the DNA methyltransferase (DNMT) family that usually occurs in cytosine bases that are immediately followed by a guanine (CpG). Large clusters of CpGs, known as CpG islands, occur in promoter regions. With some exceptions, active promoters are generally unmethylated, while inactive promoters tend to be methylated.
Several studies strongly indicate that antidepressants can induce the epigenetic modification of DNMTs, thus altering methylation levels and, subsequently, gene expression. This could explain how antidepressants modulate several molecular mechanisms and significantly affect synaptic plasticity.3,5.
A number of studies have identified epigenetic biomarkers of antidepressant response, with the majority of these studies using a targeted approach to examine a limited number of CpG sites within a specific gene locus. These gene loci include: the brainderived neurotrophic factor (BDNF);9,10 the sodium-dependent serotonin transporter (SLC6A4);1113 the serotonin receptor 1B (HTR1B);14,15 and the interleukin 11 gene (IL11).16 Recently, a genome-wide methylation study identified a set of CpG sites in specific genes such as PPFIA4 and HS3ST1 that accurately predicted paroxetine response.17
In the present study, we performed a genome-wide study assessing differences in DNA methylation that were characterized at baseline after 8 weeks of fluoxetine treatment in a homogenous sample of child and adolescent patients receiving fluoxetine for the first time.
Twenty-two children and adolescents aged between 13 and 17 years, receiving fluoxetine treatment for the first time participated in the present study. None of the participants had been treated previously with antidepressants or other psychotropic drugs. Patients were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V).18 The study was carried out at the Child and Adolescent Psychiatry and Psychology Service of the Institute of Neuroscience in Barcelona. Exclusion criteria were comorbidity with other psychiatric disorders, Tourettes syndrome, autism, somatic or neurological diseases, an intelligence quotient <70, and a non-Caucasian ethnicity. All procedures were approved by the Hospital Clnic ethics committee. Written informed consent was obtained from all the parents and verbal informed consent was given by all the participants following explanation of the procedures involved. All experiments were performed in accordance with relevant guidelines and regulations. This study was conducted in accordance with the Declaration of Helsinki.
Information on illness severity was obtained during the initial phase of the study using the following questionnaires: the Childrens Depression Inventory (CDI) for MDD patients (Kovacs, 1992) and the Childrens Yale-Brown Obsessive Compulsive Scale (CYBOCS) for OCD patients.19,20 The same scales, as well as the CGI-Improvement scale (CGI-I), were administered after 8 weeks of fluoxetine treatment. The clinical response after 8 weeks of fluoxetine treatment was evaluated using the percentage of improvement: ((CDI8weeks-CDIbasal)/CDIbasal)*100 or ((CYBOCS8weeks- CYBOCSbasal)/CYBOCS basal)*100. Patients were classified as Responders or Non-Responders according to CGI-I score after 8 weeks of fluoxetine treatment. The CGI-I scale assesses the adequacy of clinical response since the start of treatment and is rated on a 7-point scale, as follows: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change from baseline, 5=minimally worse, 6=much worse and 7=very much worse. According to this rating, and according to the literature: Responders were patients with CGI-I<2 (Very much improved or much improved) and Non-Responders were patients with CGI-I>3 (from minimally improved to very much worse).
A blood sample from each participant was collected in EDTA (BD Vacutainer K2EDTA tubes; Becton Dickinson, Franklin Lakes, New Jersey, USA) before the start of fluoxetine treatment. Genomic DNA was extracted using the MagNA Pure LC DNA Isolation Kit III and a MagNA Pure LC system (Roche Diagnostics GmbH, Mannheim, Germany). DNA concentration and quality were measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Surrey, UK).
Genome-wide DNA methylation was profiled using the Illumina Infinium MethylationEPIC BeadChip Kit carried out at CEGEN-PRB3-ISCIII. Raw.IDAT files were received and bioinformatics processes were conducted in house using the Chip Analysis Methylation Pipeline (ChAMP) Bioconductor package.21 Raw intensity data files were used to load the data into the R environment with the champ.load function, which also allows for probe QC and removal steps to occur simultaneously. Probes with low detected signals (p<0.01) (n=3302), cross reactive probes (n= 11), non-CpG probes (n=2954), probes with <3 beads in at least 5% of samples per probe (n=6891), probes that bound to SNP sites (n=96,621), and sex chromosome probes (n=61,734) are all considered problematic for accurate downstream methylation detection. After removing these probes, 739,405 probes remained for downstream analysis. Beta values were then normalized using the champ.norm function, specifically with the beta mixture quartile method (BMIQ function). Cell counts were measured using the champ.refbase function. The following cells were counted: CD8+ T cells, CD4+ T cells, natural killer (NK) cells, B cells, monocytes, and granulocytes. Next, the singular value decomposition (SVD) method was performed by champ.SVD in order to assess the amount and significance of technical batch components, along with any potential confounding variables (sex, age, diagnosis, cell count, fluoxetine dosage), in our dataset. Using the champ.runCombat function, Combat algorithms were applied in order to correct for slide and array as significant components detected by SVD. No effect of sex, age, diagnosis, cell count, or fluoxetine dosage was detected.
After filtering, normalization, and detection of batches and covariates, differentially methylated positions (DMPs) were identified using the function champ.DMP, which implements the limma package to calculate the p-value for differential methylation using a linear model. The absolute value of the difference between -value medians () of Responders and Non-Responders higher than 0.2 was set as a cut-off value to decrease the number of significant CpGs and identify sites with more biologically relevant methylation differences. Hierarchical cluster analysis of significant DMP was plotted as a heatmap and a dendrogram using the gplot and d3heatmap R packages.
Table 1 shows the sociodemographic and clinical data of the 22 participants of this study classified as Responders or Non-Responders according to the CGI-I scale after 8 weeks of fluoxetine treatment. No significant differences in age, sex, BMI, fluoxetine dose or basal clinical scores were observed between the two groups.
Table 1 Sociodemographic, Clinical and Pharmacological Data of the 22 Study Participants
We classified 47,690 probes as significant DMPs (adjusted p-values FDR<0.05): however, this included DMPs with very small differences in methylation between Responders and Non-Responders. Therefore, a > 0.2 cutoff was applied to identify 21 DMPs with methylation changes that are more likely to be biologically relevant (Table 2).
Table 2 21 Significant (FDR<0.05, > 0.2) Differentially Methylated Probes (DMPs) Between Responders and Non-Responders
We assessed the distribution of these 21 DMPs and the other probes in the array in relation to genomic regulatory elements and CpG islands. The genomic regulatory elements considered were the first exon, 3UTR, 5UTR, the gene body, and promoter-proximal regions (TSS1500 and TSS200). Hypermethylated probes in Responders were enriched in the first exon (27% vs 0.025% of all probes) and hypomethylated probes were enriched in the 5UTR (30% vs 0.08% of all probes) (Figure 1A). Regarding the CpG islands, we differentiated between CpG islands, shores (2 kbp from a CpG site), shelves (2 to 4 kbp from a CpG site) and open sea CpGs (isolated CpG in the genome). Hypermethylated probes in Responders were enriched in CpG islands (45% vs 18%) and hypomethylated probes were enriched in open sea CPGs (90% vs 58%) (Figure 1B).
Figure 1 (A) Distribution of 21 significant (FDR<0.05, > 0.2) DMPs and the rest of the probes of the array relative to regulatory elements including transcription start sites (TSS1500, and TSS200), gene body, untranscribed regions (3UTR and 5UTR) and first exon. (B) Distribution of DMPs and the rest of the probes of the array relative to CpG islands, shores, shelves, and sea.
The 21 significant CpGs mapped to 11 genes (RHOJ, RPTOR, ADAP1, SPAG1, GPR1-AS, SLC15A5, OR2L13, NDUFAF1, PPP5D1, LOX2 and ZNF697) and five intergenic regions. Two genes showed more than two significant DMPs (FDR<0.05, > 0.2) (Figure 2A). RHOJ (Ras Homolog Family Member J) presented four CpGs that were significantly hypermethylated in Non-Responders. These CpGs were in the 5-UTR and first exon of the gene, a region that, according to the UCSF browser, includes a promoter region enriched with H3K27AC marks in all cell lines considered by ENCODE (Figure 2B). Two of these CpGs (cg18771300 and cg07157030) were included in The Blood-Brain Epigenetic Concordance database (BECon; https://redgar598.shinyapps.io/BECon/)22 and showed significant correlation between methylation levels in blood and Brodmann Area 10 (BA10) and Brodmann Area 20 (BA20) (r>0.66). Both CpGs were highly variable in the blood (reference range>0.1) and fitted with the definition of a bloodbrain informative CpG in the BECon.
Figure 2 (A) Genes most enriched by the 21 significant DMPs (FDR<0.05, > 0.2). (B) Distribution of significant DMPs (FDR<0.05, > 0.2) in the RHOJ (Ras Homolog Family Member J) gene, and methylation values in Responders (RES) and Non-Responders (NORES). (C) Distribution of significant DMPs (FDR<0.05, > 0.2) in the OR2L13 (Olfactory Receptor family 2 subfamily L member 13) gene and methylation values in Responders and Non-Responders. (D) Hierarchical cluster analysis of the seven CpG sites in the RHOJ (Ras Homolog Family Member J) and OR2L13 (Olfactory Receptor family 2 subfamily L member 13) genes.
OR2L13 (Olfactory Receptor family 2 subfamily L member 13) presented three CpGs that were significantly hypomethylated in Non-Responders, located on a large CpG island in the first exon of the gene (Figure 2C). According to the BECon database, the three CpGs showed significant correlations between methylation levels in blood and the BA10, BA20 and BA7 areas (r>0.5) and were also highly variable in blood and could be considered bloodbrain informative CpGs.
As a sensitivity analysis, we tested the correlations between the methylation level of the seven CpG sites in the RHOJ (Ras Homolog Family Member J) and OR2L13 (Olfactory Receptor family 2 subfamily L member 13) genes and the percentage of improvement scored using the CDI or the CYBOCS. Significant correlations were obtained in all cases: cg03748376 (r=0.55, p=0.008), cg20507276 (r=0.54, p=0.010), cg08944170 (r=0.54, p=0.010), cg11079896 (r=0.44, p=0.038), cg07157030 (r=0.49, p=0.021), cg07189587 (r=0.48, p=0.024) and cg18771300 (r=0.43, p=0.045).
We conducted a hierarchical cluster analysis of the seven sites in these two genes RHOJ (Ras Homolog Family Member J) and OR2L13 (Olfactory Receptor family 2 subfamily L member 13). The results were expressed as a heat map indicating the methylation level at each CpG, and as a dendrogram (Figure 2D). The dendrogram clearly indicated that Responders and Non-Responders differed from each other.
To our knowledge, the present study is the first to analyze differences in DNA methylation in association with response to fluoxetine in the peripheral blood of children and adolescents using a genome-wide approach. We identified 21 CpG sites significantly (FDR<0.05) associated with fluoxetine response that showed meaningful differences (> 0.2) in methylation level between Responders and Non-Responders. Two genes, RHOJ and OR2L13, were enriched in significant CpG sites that showed a strong correlation in DNA methylation between the blood and brain (The Blood-Brain Epigenetic Concordance database BECon; https://redgar598.shinyapps.io/BECon/).
RHOJ (Ras Homolog Family Member J) is a member of the Cdc42 subfamily of the Rho family of GTPases, a group of small signaling molecules that are major regulators of cytoskeleton properties.23 Rho GTPases are involved in various cellular processes, including adhesion, cell polarization, motility and transformation, gene activation and vesicular trafficking, and have been associated with cytoskeletal organization and the regulation of axon outgrowth.24 Early studies suggested that RhoJ plays a role in modulating the formation of distinct cytoskeletal structures and lamellipodia as well as in actin filaments.25 Also, RhoJ has been shown to regulate the early endocytic pathway, being necessary for the transport of endocytosed receptors.26 Recently, the crp1 gene in Caenorhabditis elegans that encodes a protein that resembles human RhoJ has been linked to axon guidance and neuronal migration.27
OR2L13 (Olfactory Receptor family 2 subfamily L member 13) is responsible for the initialization of the neuronal response to odorants.28 Differential DNA methylation in a CpG site of this gene has been identified in multiple independent studies examining epigenetic modification in neurodevelopmental disorders.29 The CpG of interest in these studies (cg20507276) was also identified in the current study.
Our hierarchical cluster analysis indicated that methylation sites in RHOJ (Ras Homolog Family Member J) and OR2L13 (Olfactory Receptor family 2 subfamily L member 13) could be important for explaining interindividual differences in fluoxetine response. However, experimental research is needed to confirm that the methylation of these genes plays an important role in the pharmacological effect of fluoxetine and to elucidate their involvement in the mechanism of action of antidepressant drugs.
The significant CpGs identified in relation to fluoxetine in our analysis also mapped to other genes. There is some connection with neuronal physiology or pathological mechanisms of neuropsychiatric disorders for some of these genes, including ADAP1 (Stricker and Reiser, 2014), SPAG1, SLC15A5 and RPTOR.3033 For the other genes (GPR1-AS, NDUFAF1, PPP5D1, LOX2 and ZNF697) or intergenic regions identified we have little or no information about their physiological connection with the pharmacological effect of fluoxetine or their role in the pathophysiology of neuropsychiatric disorders.
To our knowledge, this study is the first genome-wide DNA methylation study of fluoxetine response in children and adolescents. The major strength of our study was that several potential confounders were controlled for, such as age, smoking status, pharmacological treatment and the course of the disease. Our sample contained children and adolescents of similar ages who had not previously been treated with antidepressants or other psychotropic drugs and who were at the initial stages of the illness. We also controlled for blood cell composition, as DNA methylation is cell-type specific and different cell compositions between samples could affect the methylation data obtained.
However, the findings of this study should be interpreted by bearing in mind several important limitations. The sample size limited the statistical power of the study and made it difficult to detect small or modest effects on DNA methylation. Given that the study was hypothesis-driven and due to the small sample size, our results should be seen as preliminary and should be considered as exploratory findings that require further confirmation. Our study had several limitations. We used peripheral blood even though DNA methylation is known to be tissue-specific. However, blood is considered to be a useful proxy for detecting changes across tissues and is the most appropriate tissue in which to look for biomarkers. Moreover, there is a moderate correlation between blood and the brain for non-specific regulatory regions across the methylome.22 Third, the observation period was eight weeks, which could not be enough to detect long-term epigenetic changes. Finally, our study included patients with different diagnoses, MDD and OCD. For this reason, in the primary analysis, Responders and Non-Responders were defined according to the CGI-I scale. However, the sensitivity analysis, replacing the dichotomous classification of patients according to the CGI by the symptoms improvement scored using the CDI and the CYBOCS, confirms our significant findings.
In conclusion, our findings provide new insights into the molecular mechanisms underlying the complex phenotype of antidepressant response and suggest that methylation at specific genes, such as (RHOJ and OR2L13) could become potential biomarkers for predicting antidepressant response. However, the replication of our results in large samples is necessary in order to include the methylation level of these specific genes as biomarkers to develop predictors for clinical applications.
The authors thank the Language Advisory Service at the University of Barcelona for manuscript revision. The authors also thank all subjects and their families for the time and effort spent on this study.
Rodriguez N and Martnez-Pinteo A participated carrying out the experimental procedures, performing the bioinformatic analyses and the interpretation of results and wrote the first draft of the manuscript.
Gass P helped in performing the statistical analyses and the interpretation of results and helped in drafting the manuscript.
Blzquez A, Varela E and Plana MT participated in the recruitment and assessment of the sample and helped in drafting the manuscript.
Lazaro L participated in the coordination of the recruitment and assessment of the sample, the maintenance of the database, acquisition of funding, and helped in drafting the manuscript.
Lafuente A participated in helping in conceiving, designing and coordinating the whole study, interpreting the results and drafting the manuscript.
Mas S conceived and designed the whole study and participated in performing the statistical analysis, interpretation of results and wrote the first draft of the manuscript.
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval for the version to be published; and agree to be accountable for all aspects of the work.
This work was supported by the Alicia Koplowitz Foundation; Ministerio de Economa y Competitividad-Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (FEDER)-Unin Europea (PI16/01086). Support was also given by the CERCA Programme/the Government of Catalonia, Secretaria dUniversitats i Recerca del Departament dEconomia i Coneixement to the Child Psychiatry and Psychology Group (2017SGR881) and to the Clinical Pharmacology and Pharmacogenetics Group (2017SGR1562). Funding sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Dr Natalia Rodriguez reports grants from Alicia Koplowitz Foundation, Ministerio de Economa y Competitividad-Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (FEDER)- Unin Europea, and non-financial support from CERCA Programme/the Government of Catalonia, Secretaria dUniversitats i Recerca del Departament dEconomia i Coneixement, during the conduct of the study. The authors reported no other potential conflicts of interest for this work.
1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:19051917. doi:10.1176/ajp.2006.163.11.1905
2. Mrazek DA, Biernacka JM, McAlpine DE, et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol. 2014;34:313317. doi:10.1097/JCP.0000000000000099
3. Belzeaux R, Lin R, Ju C, et al. Transcriptomic and epigenomic biomarkers of antidepressant response. J Affect Disord. 2018;233:3644. doi:10.1016/j.jad.2017.08.087
4. Gadad BS, Jha MK, Czysz A, et al. Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks. J Affect Disord. 2018;233:314. doi:10.1016/j.jad.2017.07.001
5. Fabbri C, Serretti A. Clinical application of antidepressant pharmacogenetics: considerations for the design of future studies. Neurosci Lett. 2018;726. doi:10.1016/j.neulet.2018.06.020.
6. Fabbri C, Tansey KE, Perlis RH, et al. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics J. 2018;18:413421. doi:10.1038/tpj.2017.44
7. Uher R, Tansey KE, Henigsberg N; GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207217. doi:10.1176/appi.ajp.2012.12020237
8. Lisoway AJ, Zai CC, Tiwari AK, Kennedy JL. DNA methylation and clinical response to antidepressant medication in major depressive disorder: a review and recommendations. Neurosci Lett. 2018;669:1423. doi:10.1016/j.neulet.2016.12.071
9. Tadi A, Mller-Engling L, Schlicht KF, et al. Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Mol Psychiatry. 2014;19:281283. doi:10.1038/mp.2013.58
10. Wang P, Zhang C, Lv Q, et al. Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients. Eur J Clin Pharmacol. 2018;74:10111020. doi:10.1007/s00228-018-2463-z
11. Domschke K, Tidow N, Schwarte K, et al. Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychopharmacol. 2014;17:11671176. doi:10.1017/S146114571400039X
12. Kang HJ, Kim JM, Stewart R, et al. Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:2328. doi:10.1016/j.pnpbp.2013.01.006
13. Okada S, Morinobu S, Fuchikami M, et al. The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression. J Psychiatr Res. 2014;53:4753. doi:10.1016/j.jpsychires.2014.02.002
14. Wang P, Lv Q, Mao Y, et al. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients. J Affect Disord. 2018;228:222228. doi:10.1016/j.jad.2017.12.010
15. Gass P, Rodrguez N, Blzquez A, et al. Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75:2834. doi:10.1016/j.pnpbp.2016.12.003
16. Powell TR, Smith RG, Hackinger S. Hackinger Set al. DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl Psychiatry. 2013;3:e300. doi:10.1038/tp.2013.73
17. Takeuchi N, Nonen S, Kato M, et al. Therapeutic response to paroxetine in major depressive disorder predicted by DNA methylation. Neuropsychobiology. 2017;75:8188. doi:10.1159/000480512
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th. American Psychiatric Press; 2013.
19. Kovacs M. Childrens Depression Inventory Manual. New York, NY: Multi Health Systems; 1992.
20. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Childrens yale-brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36:844852. doi:10.1097/00004583-199706000-00023
21. Tian Y, Morris TJ, Webster AP, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33:39823984. doi:10.1093/bioinformatics/btx513
22. Edgar RD, Jones MJ, Meaney MJ, Turecki G, Kobor MS. BECon: a tool for interpreting DNA methylation findings from blood in the context of brain. Transl Psychiatry. 2017;7:e1187. doi:10.1038/tp.2017.171
23. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629635. doi:10.1038/nature01148
24. Azzarelli R, Kerloch T, Pacary E. Regulation of cerebral cortex development by Rho GTPases: insights from in vivo studies. Front Cell Neurosci. 2015;8:445. doi:10.3389/fncel.2014.00445
25. Shi TT, Li G, Xiao HT. The role of RhoJ in endothelial cell biology and tumor pathology. Biomed Res Int. 2016;6386412. doi:10.1155/2016/6386412
26. de Toledo M, Senic-Matuglia F, Salamero J, et al. The GTP/GDP cycling of rho GTPase TCL is an essential regulator of the early endocytic pathway. Mol Biol Cell. 2003;14:48464856. doi:10.1091/mbc.e03-04-0254
27. Alan JK, Robinson SK, Magsig KL, Demarco RS, Lundquist EA. The atypical Rho GTPase CHW-1 works with SAX-3/robo to mediate axon guidance in Caenorhabditis elegans. G3 (Bethesda). 2018;8:18851895. doi:10.1534/g3.118.200148
28. Berko ER, Suzuki M, Beren F, et al. Mosaic epigenetic dysregulation of ectodermal cells in autism spectrum disorder. PLoS Genet. 2014;10:e1004402. doi:10.1371/journal.pgen.1004402
29. DallAglio L, Muka T, Cecil CAM, et al. The role of epigenetic modifications in neurodevelopmental disorders: a systematic review. Neurosci Biobehav Rev. 2018;94:1730. doi:10.1016/j.neubiorev.2018.07.011
30. Stricker R, Reiser G. Functions of the neuron-specific protein ADAP1 (centaurin-1) in neuronal differentiation and neurodegenerative diseases, with an overview of structural and biochemical properties of ADAP1. Biol Chem. 2014;395:13211340. doi:10.1515/hsz-2014-0107
31. Chatterton Z, Hartley BJ, Seok MH, et al. In utero exposure to maternal smoking is associated with DNA methylation alterations and reduced neuronal content in the developing fetal brain. Epigenetics Chromatin. 2017;10:4. doi:10.1186/s13072-017-0111-y
32. Maul S, Giegling I, Fabbri C, Corponi F, Serretti A, Rujescu D. Genetics of resilience: implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression. Am J Med Genet B Neuropsychiatr Genet. 2020;183:7794. doi:10.1002/ajmg.b.32763
33. Kosillo P, Doig NM, Ahmed KM, et al. Tsc1-mTORC1 signaling controls striatal dopamine release and cognitive flexibility. Nat Commun. 2019;10:5426. doi:10.1038/s41467-019-13396-8
Read more from the original source:
[Full text] DNA Methylation of Fluoxetine Response in Child and Adolescence: Preli | PGPM - Dove Medical Press
Posted in DNA
Comments Off on [Full text] DNA Methylation of Fluoxetine Response in Child and Adolescence: Preli | PGPM – Dove Medical Press
Proving a Connection to Enslaved Ancestors Through DNA – The Wall Street Journal
Posted: at 7:12 am
Building a family tree depends on access to historical records, which can be problematic for Black Americans whose ancestors were enslaved. Before the Civil War and emancipation in 1863, slaves were considered property and werent included by name in many records. In the absence of clear records about genealogy, DNA can help fill in the gaps regarding family relationships.
LaBrenda Garrett-Nelson wanted to establish that Samuel and Nancy Garrett, an enslaved couple, were the parents of Isaac Garrett, her great-great-grandfather.
Once a practicing lawyer, she was used to painstakingly searching for evidence. Now working as a certified genealogist specializing in tracing African-American families that came out of slavery, she knew how difficult it could be. Even after years of effort, she couldnt fill out every branch of her own family tree. In the search for documents about the couple, there were 28 years unaccounted for before they turned up in official records after the end of slavery.
Ms. Garrett-Nelson hoped DNA tests could help her fill in the gaps and connect Isaac with his parents.
DNA tests are a critical tool to help identify and establish family ties disrupted or severed by slavery, said Melvin Collier, a genealogist in Washington, D.C., who shares tips about researching African enslaved ancestors on his blog, Roots Revealed, and has written three books on the subject.
See the rest here:
Proving a Connection to Enslaved Ancestors Through DNA - The Wall Street Journal
Posted in DNA
Comments Off on Proving a Connection to Enslaved Ancestors Through DNA – The Wall Street Journal
A DNA Zoo Maps the Mysteries of All Creatures Great and Small – Texas Monthly
Posted: at 7:12 am
Marveling at the size of the elephants or squealing at the cuteness of the meerkats, visitors come regularly to the Houston Zoo for the chance to observe exotic animals up-close. Meanwhile, just a few blocks away, a laboratory houses a markedly different sort of zoo. Instead of furry and feathered creatures in enclosures, there are thousands of blood samples in a pair of freezers surrounded by dozens of white boards covered by mathematical equations.
This is the DNA Zoo, where a team of thirty-plus scientists use cutting-edge genomic technology in service of boosting the survival chances for countless endangered specieswork that could contribute to human health as well. The lab has acquired genetic samples of 4,234 animals representing 1,105 species, largely obtained from zoos and parks including the Houston Zoo, San Antonio Zoo, Sea World, and the Texas State Aquarium. In 2019, they opened a counterpart lab in Australia to focus on species unique to that continent.
Humans are essentially one of natures experiments, says Erez Lieberman Aiden, founder of the Aiden Lab at the Center for Genome Architecture at Baylor College of Medicine, which runs the DNA Zoo. Nature has performed many, many, many experiments, and we can learn from the experiments that nature has performed on other species.
Over the course of five years, beginning in 2011, Aiden and his team developed technology that allows them to sequence DNA in days, instead of the usual weeks, and at a cost of hundreds of dollars, rather than hundreds of thousands.
It took thirteen years to sequence the human genome and another four years for the corn genome, but you ended up with a similar quality of work to what the DNA Zoo is doing now in a matter of days, says Blake Hanson, an associatedirectorof microbial genomics at the University of Texas Health Science Center in Houston.
Aiden, who built a scale model of DNA for a science fair in high school, remembers becoming truly fascinated during graduate schoolhe holds doctorates from Harvard and MITwith how a DNA strand as long as six feet could fold inside a single cell. His studies led to genome mapping technology he dubbed Hi-C (after the fruity drink, a favorite of his) and Juicebox, software that facilitates the three-dimensional assembly of a DNA strand.
Genome sequencing requires disassembling and reassembling strands of DNA in order to fully understand how each of those segments relate to one another. Some segmentsknown as repeats or regions of low complexityare nearly impossible to distinguish from others. If you have a jigsaw puzzle thats like pure black, it becomes really hard because a piece can go anywhere, Aiden says. The algorithms built into Hi-C and Juicebox allow his team to solve that puzzle by ferreting out subtle patterns in the DNA that are otherwise extremely difficult to detect.
The DNA Zoos work assists zoos and other wildlife parks in their conservation efforts. For instance, Aidens team has sequenced the genes of all the elephants at the Houston Zoo, which helps in determining which of the animals should be bred with one another to keep the gene pool diverse, preventing the animals that mate from being too closely related. The DNA Zoo wont be the only piece we need to preserve the genomes of these animals to push forward the idea of conservation, but it is a huge piece in that puzzle, Hanson says.
Furthermore, by making its collection of sequenced genomes publicly available, the DNA Zoo provides vital data to researchers looking to combat diseases, both in animals and humans. In 2015, Aiden and his team helped scientists map the DNA of the mosquito species that carried the Zika virus, an epidemic at the time. Aiden is enthusiastic in his explanation of how genomic technology is already changing the face of health care. Its literally a very straight line from the release of the genome of the SARS-CoV-2 virus to the vaccine, he says of how similar knowledge has been deployed by others in the COVID-19 pandemic.
The DNA Zoo is hardly the first program to sample and store animal blood for scientific study. The Cryo-Zoo at the MD Anderson Cancer Center, which collaborates with the DNA Zoo, was founded by biologist T.C. Hsu in the 1970s. Hsu was a pioneer in studying animal chromosomes and collected them from thousands of species. Forty years ago, most zoos were much smaller and less involved in conservation efforts than they are today. As a result, many animal samples had to be acquired in the wild, which could be rather difficult.
They would go places, like classical adventure-type stories, says Olga Dudchenko, co-founder of the DNA Zoo. Somebody would get stranded on a boat for several days without water and food trying to get some cells from some rodent in South Africa.
Even today, its not always as simple as drawing blood from animals at zoos. Scientists sometimes have to get creative. In the case of the southern right whaleso named because whalers considered it a good target (i.e. the right whale to hunt), nearly hunting it to extinction in the twentieth centurythere are none in captivity. So how do you get a DNA sample from a sixty-foot, ninety-ton animal swimming through the ocean? Out of the blowhole. Just as humans expel DNA when we sneeze, whales expel it when they breathe, and that can be collected by nearby scientists.
The highly technical efforts of the DNA Zoo are sometimes difficult to explain to the layperson, so the lab has employed more down-to-earth approaches in reaching out to both the scientific community and the world at large. Lab members write regular blog posts about the new sequences they have completed, which contain the complex language of scientists, but also fun facts about the species. A typical post, in February, featured an adorable photo of a mouse. Weighing about as much as six paper clips, the text explained, the endangered Pacific pocket mouse (PPM) aka Perognathus longimembris pacificus is the among the smallest rodents in the world.
The DNA Zoo has even produced a comic strip called ChromoGnomes, drawn by Adam Fotos, a comic book artist in Chicago. It tells of a pair of gnomes attempting to create various animals from their genetic code with varying degrees of success. The lab hopes it will make what they do more accessible to those without advanced degrees in biology and computer science.
Similar to what we do with blog posts, we can do this in a more fun and visual way, Dudchenko says. So far, theyve only published four installments of the strip, though more are promised. It turns out that writing comics is more difficult right now for us then creating genome assemblies.
Fortunately, the Aiden team appears quite skilled at assembling DNA sequences. They convey excitement about where it all might lead, perhaps even into the realm of what sounds like science fiction. The ultimate goal is that if we read through the genomes really, really well, and probably in a few years, well be able to not just read but also generate DNA, Dudchenko says. In theory, you can re-create just from the seed, re-create species just from the sequence.
This notion conjures images from Jurassic Park, the Michael Crichton novel that envisioned a world where dinosaurs could be replicated from the DNA of long-dead mosquitoes trapped in amber. It might someday not be quite as far-fetched as when the book came out.
Recently, in fact, a group of scientists who are collaborators with the DNA Zoo set a record by reading the DNA from a sample that was estimated to be a million years old. Its not like we would say no to Jurassic Park-level DNA, Dudchenko says. Its too juicy a topic.
Read the original post:
A DNA Zoo Maps the Mysteries of All Creatures Great and Small - Texas Monthly
Posted in DNA
Comments Off on A DNA Zoo Maps the Mysteries of All Creatures Great and Small – Texas Monthly
DNA Test Leads to a Kidney Donation and Second Chance at Life – The Wall Street Journal
Posted: at 7:12 am
More than 7,000 living donors give a kidney or part of a liver each year to a blood relative in the U.S., according to the United Network for Organ Sharing. In the era of DNA testing, as families circles widen to discover new blood relations, the potential for donor matches will increase.
On a Thursday morning in 2016, Mindy Towns prepared to make a phone call that would end up taking her to a hospital bed halfway across the country. She couldnt have known it, but she was about to connect with a seriously ill half-brother who had lost nearly everything in a plane crasheven, perhaps, his will to live.
On this February morning, Ms. Towns was simply looking to connect with the man she believed to be her birth father. Now 56 years old, she had grown up in an era when most adoption records were secret. It had taken her more than 30 years of sleuthing to find Daryl Wedan.
To prove it, I was going to have to call him, Ms. Towns said. It was the longest day of my life. I set up my computer with the family tree and papers. I was so nervous, I wrote myself a script.
When he got the call, Mr. Wedan hung up on her. I was actually at my grandsons karate class, he said. I thought it was a sales call or something, and I didnt quite hear her properly so I hung up on her. Later I saw it was a Florida number, and I thought I better call that number back.
The rest is here:
DNA Test Leads to a Kidney Donation and Second Chance at Life - The Wall Street Journal
Posted in DNA
Comments Off on DNA Test Leads to a Kidney Donation and Second Chance at Life – The Wall Street Journal
We studied the DNA of African and Asian leopards and found big differences between the two – The Conversation Africa
Posted: at 7:12 am
Leopards are among the most widespread carnivores today, living in a wide range of habitats, from deserts to rainforests, and from the lowland plains to the mountainous highlands.
Over the past century, theyve experienced extreme habitat losses due to human activity, both directly from hunting and indirectly from habitat reduction and prey competition. This has led to the land they occupy being reduced by over 50% in Africa, and over 80% in Asia, involving the local extinction of many populations.
Genetic analysis of leopards is important to understand their population history, structure and dynamics. Particularly important is the analysis of whole nuclear genomes, which means all the DNA contained in the cell core approximately 2.5 billion DNA bases (pairs of DNA building blocks).
In new research, we studied the genomes of modern and historical leopards, using samples gathered from an unusual place natural history museums. And we found a surprising level of genetic separation between leopards from different parts of the world.
Normally, genetic analysis involves collecting fresh tissue samples. For leopards, doing this would be extremely difficult. The animals are hard to track down, particularly in areas where they are rare, and invasive sampling can be bad for the animal.
Animals bred in zoos may not be a good option as they may be mixtures of multiple wild populations. Getting samples from areas where they have been eradicated is not possible at all. For these reasons, we turned our sampling efforts to museums.
Natural history museums across the world are filled with skins, skeletons and even complete taxidermy specimens, often collected decades and decades ago. Its a lot more challenging to extract genetic material from these old specimens, both from a technical and a financial point of view, because the DNA in such samples is more degraded, and sometimes includes large amounts of contaminant DNA in addition to the leopard DNA. But doing so allowed us to collect data from leopards covering their entire distribution, both current and historical.
This would have been near impossible if we only looked for fresh tissue samples. The collection of this genetic data allowed us to investigate the global population dynamics of leopards, with unprecedented resolution.
We collected material from many museum specimens, and investigated the DNA quality in each. Then, we selected the best samples from which to sequence hundreds of billions of bases of DNA. Using high powered computational resources we compared the DNA from all leopards to each other, and ran a range of different types of analyses to better understand how they differ.
One of the most striking revelations we found was a marked distinction between African and Asian leopards. In fact, at the genome wide scale across most of the leopards 2.5 billion DNA bases Asian leopards are more genetically separated from African leopards than brown bears are from polar bears.
Adding to the puzzle is the comparatively recent divergence of African and Asian leopards, approximately 500,000 to 600,000 years ago, which is comparable to that between modern humans and Neandertals. Brown bears and polar bears, in contrast, diverged around 1 million years ago.
Read more: We sequenced the cave bear genome using a 360,000-year-old ear bone and had to rewrite their evolutionary history
The cause of this genetic differentiation of Asian leopards is their out-of-Africa dispersal. Although the evidence suggests that leopards in south-western Asia carry DNA thats relatively similar to African leopards, which could be due to occasional interbreeding, the overall distinctiveness of leopards on the two continents has been maintained. We would have expected Asian and African leopards to show more similarities in their DNA, as there has been (and possibly still is) mixing between the populations.
This level of separation is unexpected within a single species. Such a genetic distinction is not even always clear between different species. It also shows a brief event with relatively few individual leopards the out-of-Africa dispersal has had a massive influence on shaping the genetic patterns of these animals across the world.
A second important result is that African and Asian leopards have had a very different population history since their separation. African leopards show higher genetic variability, and their populations are less genetically distinct from one another.
In Asia, theres a much stronger effect of geography, meaning that the correlation between genetic distance and geographic distance is stronger. Leopards are generally genetically more similar to other leopards that live close by, than those that live far away. This suggests less gene flow and dispersal between different parts of the continent than in Africa.
Despite the extensive encroachment by humans on leopard habitats, the historical samples didnt necessarily have a higher genetic diversity than the modern samples included in the study. This shows that the differences we see in Asian leopards is not due to recent human impacts. Although humans have driven some local leopard populations to extinction, the impact of humans on the species as a whole is not yet severe enough to be reflected in the entire genome.
The leopard samples from the museum shelves have given us valuable new insights into their evolutionary history, as well as current populations across the world even populations weve driven to extinction. Leopards are listed on the IUCN red list of threatened species, and classed as critically endangered for some of their range.
Considering the impact we humans have had on wildlife in recent centuries, there may be many species for which there are exciting genetic discoveries hidden among the shelves of natural history museums around the world.
Read the original:
We studied the DNA of African and Asian leopards and found big differences between the two - The Conversation Africa
Posted in DNA
Comments Off on We studied the DNA of African and Asian leopards and found big differences between the two – The Conversation Africa
Traces of Ancient Epidemic Detected in DNA – Archaeology
Posted: at 7:12 am
TUCSON, ARIZONAAccording to a Science News report, traces of a viral epidemic some 25,000 years ago have been detected in the DNA of present-day East Asians. Evolutionary geneticist David Enard of the University of Arizona and his colleagues analyzed more than 2,000 publicly available DNA samples from Chinese Dai, Vietnamese Kinh, and African Yoruba people for more than 400 proteins known to interact with coronaviruses. The researchers found that only the East Asian groups showed substantially increased production of all of the proteins. Analysis of the genes related to the production of these proteins suggests they became more common about 25,000 years ago and then leveled off about 5,000 years ago. This indicates that East Asians could have adapted to the infection, or the virus became a less potent cause of disease, Enard explained. Some of the gene variants would have also been useful for fighting other types of viruses as well, he added. Further study is needed to determine if these gene variants offer any protection against SARS-CoV-2, the virus that causes COVID-19. To read about a sixteenth-century epidemic in Mexico, go to "Conquistador Contagion."
Read this article:
Traces of Ancient Epidemic Detected in DNA - Archaeology
Posted in DNA
Comments Off on Traces of Ancient Epidemic Detected in DNA – Archaeology
Dynasty draft DNA: Identifying the traits that make up the future elite fantasy football stars – The Athletic
Posted: at 7:12 am
Aim small, miss small.
The application of that phrase originally applied to aiming a muzzle-loader rifle. The concept being that instead of aiming broadly at your target, aim at something very small on your target so that should you miss, you still hit your target. While I have no muzzle-loader experience, I still find the phrase applies to my draft preparation.
Ive always been fond of player scouting dating back to the late 1990s, and Ive been a fan of statistical modeling for long before that. Combining these two passions has made for a great foundation for success at fantasy football, where leveraging my objectivity and available data has allowed me to gain an edge over my competition. Look around the fantasy multiverse and youll see a broad array of data points, metrics and applications bandied about as the secret sauce to winning.
Read more from the original source:
Dynasty draft DNA: Identifying the traits that make up the future elite fantasy football stars - The Athletic
Posted in DNA
Comments Off on Dynasty draft DNA: Identifying the traits that make up the future elite fantasy football stars – The Athletic